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Summary
Introduction. — Conflicting data exist on the risk of stent thrombosis with drug-eluting stents
(DES) versus bare-metal stents (BMS). Little is known about the potential different characteristics
and outcomes of DES versus BMS thrombosis.
Objective. — To compare the characteristics, timing and outcomes of patients with angiographic
stent thrombosis according to type of stent implanted.
Methods. — The population comprised consecutive patients who underwent BMS or DES
implantation (January 2003-April 2007) at Pitié-Salpêtrière Hospital. Data from patients with
and without a stent thrombosis were compared to identify predictors of thrombosis. Timing of
thrombosis (acute, <24 hours; subacute, <30 days; late, >30 days; very late, >1 year), clinical,
angiographic and procedural characteristics, and outcomes were compared between patients
with a BMS or DES thrombosis. 
Results. — A total of 3579 patients received a BMS (2815 lesions, 2318 patients) or a DES (1536
lesions, 1261 patients). Documented angiographic stent thrombosis occurred in 52 (1.4%)
patients, 16 (1.3%) with a DES and 36 (1.6%) with a BMS. Rates of acute (0.1% versus 0.2%),
subacute (1% versus 0.7%), late (both 0.2%) and very late (both 0.2%) thrombosis were similar
in patients with BMS and DES thrombosis. Factors predictive of stent thrombosis were similar,
including left ventricular failure (P<0.0001), initial percutaneous coronary intervention (PCI)
for acute myocardial infarction (P<0.0001), multivessel PCI (P<0.0001), and balloon dilatation
before stenting (P<0.04). Eleven (21%) cases of BMS (n=8, 22%) or DES (n=3, 19%) thrombosis
arose soon after stopping antiplatelet therapy. Thirteen of 52 (25%) patients died a few hours
after the event. Twenty-seven (52%) major adverse cardiac events occurred at 18 months, 7 in
patients with a DES and 20 in those with a BMS (44% versus 55%, P=NS). These included 16 deaths
(31%), 7 repeat PCIs and 4 myocardial infarctions. There were no independent predictive
factors of death after stent thrombosis.
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Conclusions. — BMS and DES thrombosis are similar in terms of timing of thrombosis,
characteristics and outcomes, and share the same risk of late thrombosis after interruption of
antiplatelet therapy.
© 2008 Published by Elsevier Masson SAS.
Résumé 
Introduction. — Les risques respectifs de thrombose de stents actifs (DES) et conventionnels
(BMS) sont controversés. Peu de données sont disponibles sur la comparaison des
caractéristiques et du pronostic des patients avec thrombose de DES ou BMS.
Objectif. — Comparer les caractéristiques, le délai et le pronostic des patients avec thrombose
de stent documentée à l’angiographie selon le type de stent.
Méthodes. — L’étude a porté sur tous les patients traités par angioplastie avec DES ou BMS à
l’Hôpital de la Pitié-Salpêtrière entre janvier 2003 et avril 2007. Les facteurs prédictifs de
thrombose ont été identifiés en comparant les patients avec et sans thrombose de stent. Les
patients avec thrombose de DES ou BMS ont été comparés en terme de délai de thrombose
(aiguë, < 24 heures ; subaiguë, < 30 jours ; tardive, > 30 jours ; très tardive, > 1 an), de
caractéristiques cliniques, angiographiques et de procédure, ainsi que de pronostic.
Résultats. — 3 579 patients ont été inclus, 2 318 avec BMS (2 815 lésions) et 1 261 avec DES
(1 536 lésions).Une thrombose de stent documentée à l’angiographie est survenue chez
52 patients (1,4 %), 16 (1,3 %) avec un DES et 36 (1,6 %) avec un BMS. Les taux de thrombose
aiguë (0,1 % vs 0,2 %), subaiguë (1 % vs 0,7 %), tardive (0,2 % vs 0,2 %) ou très tardive (0,2 % vs
0,2 %) ont été comparables chez les patients avec thrombose de BMS ou DES. Les facteurs
prédictifs de thrombose de DES et BMS étaient semblables, incluant la dysfonction ventriculaire
gauche (p < 0,0001), l’angioplastie initiale pour infarctus aigu (p < 0,0001), l’angioplastie
pluritronculaire (p < 0,0001) et l’angioplastie au ballon avant stent (p < 0,04). Onze cas (21 %)
de thrombose de BMS (n = 8, 22 %) ou de DES (n = 3, 19 %) sont survenus juste après l’arrêt du
traitement antiagrégant plaquettaire. Treize des 52 patients (25 %) sont décédés quelques
heures après la thrombose de stent. Un événement cardiaque majeur est survenu à 18 mois
chez 27 patients (52 %), 7 après thrombose de DES et 20 après thrombose de BMS (44 % vs 55 %,
p = NS), dont 16 décès (31 %), 7 nouvelles angioplasties et 4 infarctus. Il n’a pas été identifié
de facteur indépendant prédictif de décès après thrombose de stent.
Conclusions. — Les patients avec thromboses de BMS ou DES sont comparables en termes de
délais, caractéristiques et pronostic, avec le même risque de thrombose tardive après arrêt du
traitement antiagrégant plaquettaire.
© 2008 Published by Elsevier Masson SAS.
Introduction
The introduction of drug-eluting stents (DES) has led to a
dramatic reduction in the rate of restenosis in comparison
with bare-metal stents (BMS) [1]. By the end of 2004, DES
were used in nearly 80% of percutaneous coronary interven-
tions (PCI) in the USA, and within 3 years, several million
DES had been implanted worldwide. A meta-analysis of
10 randomized trials confirmed the efficacy and safety pro-
file of these devices, but the trials were not powered to
detect or exclude the effect of DES on rare events such as
stent thrombosis [2]. 
The timing of stent thrombosis is highly variable, ranging
from “acute” to “late”. Conflicting results have been repor-
ted on an increased risk of late stent thrombosis with DES
compared with BMS [3-10]. In several pooled analyses of ran-
domized studies [3-5], for example, the rates of stent throm-
bosis did not differ between BMS and DES, whereas late
thrombosis appeared to be more frequently associated with
DES in one trial [6]. Similarly, no statistically significant dif-
ference was found between the two devices in rates of stent
thrombosis in three registry studies [8-10], whereas DES
were associated with an increased risk in a Swedish registry
[7]. The aim of our study was to compare the clinical, angio-
graphic and procedural characteristics, timing of stent
thrombosis, and clinical outcomes of patients with stent
thrombosis according to whether they had a DES or BMS.
Methods
The study population comprised 3 579 consecutive patients
who underwent BMS (2 815 lesions treated in 2 318 patients)
or DES (1 536 lesions in 1 261 patients) implantation at our
institution between January 2003 and April 2007. All patients
were treated with aspirin and clopidogrel (chronic treatment
or loading dose at least 6 hours before the intervention). The
type of stent (BMS or DES) selected and the use of glycopro-
tein IIb/IIIa inhibitors was at the physician’s discretion. In
most cases, DES were selected in accordance with French gui-
delines which took into account proximal left anterior des-
cending artery, diabetes, vessel diameter <3 mm, lesion
length >15 mm, and in-stent restenosis. After stent implanta-
tion, all patients were treated with clopidogrel and aspirin.
Treatment with aspirin was continued indefinitely. In most
patients, clopidogrel treatment was stopped 1 month after
BMS implantation, and 6 to 12 months after DES implantation.
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Definitions
Stent thrombosis was defined as in-stent thrombosis confir-
med angiographically, with or without vessel occlusion, and
associated with clinical or electrocardiographic signs of acute
ischaemia or elevation of creatinine kinase levels to twice the
normal value within 48 hours of angiography (i.e. “definite”
stent thrombosis according to the Academic Research Consor-
tium [ARC] definition, 2006).[ref?] Partial thrombosis refer-
red to an intrastent filling defect with a TIMI flow of 1 to 3 in
the coronary artery, and total stent occlusion referred to
intrastent thrombosis with a TIMI flow of 0. Patients with pro-
bable or possible stent thrombosis according to the ARC y. 
Timing of stent thrombosis was categorized according to
the ARC definitions as acute (<24 hours), subacute (<30 days),
late (>30 days) and very late (>1 year) after implantation. Cli-
nicaldefinition, which corresponded to unexplained death ≤30
days or >30 days after initial PCI, were not included in this
stud, angiographic and procedural characteristics were com-
pared in patients with or without stent thrombosis, and accor-
ding to the type of stent used in those with a thrombosis. 
Chronic renal failure was defined as a serum creatinine
concentration >1.5 mg/dL for men and >1.3 mg/dL for
women. Prior left ventricular failure was defined as clinical
symptoms occurring during, or leading to, hospitalization. 
Statistical analyses
Continuous variables are presented as means (standard
deviations). Categorical data are presented as per cent fre-
quencies. Univariate analyses were performed using the χ2
test for categorical data with Yates correction if needed, and
analysis of variance for continuous variables with Fisher’s
exact test if needed. A univariate analysis that included
23 clinical, biological, angiographic and procedural variables
(tables 1, 2 and 3) was performed to identify the best set of
predictors for occurrence of cardiac death after stent throm-
bosis. A Cox model was performed to identify independent
predictors of cardiac death after stent thrombosis. Survival
curves were constructed using the Kaplan-Meier actuarial
method, and comparisons between groups were obtained
with the log-rank statistic. All calculations were performed
with StatView 5.0 (SAS institute Inc., Cary, NC). A probability
of P <0.05 was considered statistically significant.
Results
Over a follow-up period of 51 months, a documented angio-
graphic stent thrombosis occurred in 52 (1.4%) patients, 16
(1.3%) with a DES and 36 (1.6%) with a BMS. The rates of
acute (n=3, 0.1% versus n=2, 0.2%), subacute (n=24, 1% ver-
sus n=9, 0.7%), late (n=5, 0.2% versus n=2, 0.2%) and very
late thrombosis (n=4, 0.2% versus n=3, 0.2%) were similar in
patients with BMS or DES thrombosis. 
The baseline characteristics of patients with and without
a stent thrombosis are listed in table 1. Stent thrombosis
was more frequent in men (P<0.04), in patients with a pre-
vious myocardial infarction (P<0.0001), with clinical left
ventricular failure before the initial PCI (P<0.0001), initial
Table 1 Baseline characteristics and procedural data: comparison between patients with and without
stent thrombosis.
With stent
thrombosis
(n=52)
Without stent 
thrombosis 
(n=3527)
P
Age (years)±SD 60±14 63±11 0.06
Men, n (%) 49 (92) 2832 (80) <0.04
Diabetes mellitus, n (%) 20 (38) 1105 (31) NS
Hypertension, n (%) 28 (54) 1799 (51) NS
Smoking history, n (%) 27 (52) 1353 (38) 0.06
Prior CABG, n (%) 4 (8) 276 (8) NS
Prior MI, n (%) 34 (65) 772 (22) <0.0001
Chronic renal failure 6 (11) 560 (16) NS
Prior left ventricular failure, n (%) 16 (31) 397 (11) <0.0001
PCI for acute MI, n (%) 28 (54) 928 (26) <0.0001
IV antiplatelet therapy during initial PCI, n (%) 24 (46) 1078 (31) NS
Bifurcation/ostial lesion, n (%) 10 (19) 388 (11) 0.09
Multivessel PCI, n (%) 24 (46) 606 (17) <0.0001
PCI with >1 stent, n (%) 22 (42) 1049 (30) 0.07
Direct stenting, n (%) 29 (56) 2469 (70) 0.04
Stent diameter (mm)±SD 2.9±0.3 3±0.3 <0.02
Drug-eluting stent, n (%) 16 (31) 1245 (35) NS
CABG: coronary artery bypass graft; MI: myocardial infarction; NS: non-significant; PCI: percutaneous coronary intervention; 
SD: standard deviation.
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PCI for acute myocardial infarction (P<0.0001), balloon
dilatation before stenting (P<0.04), smaller diameter stents
(P<0.02), and multivessel PCI (P<0.0001).
The baseline characteristics of patients with BMS or DES
thrombosis are compared in table 2. Eleven (21%) cases of
BMS (n=8) or DES (n=3) thrombosis arose soon after antipla-
telet therapy was interrupted. Most of the predictive fac-
tors for stent thrombosis, including male sex, prior myocar-
dial infarction, prior left ventricular failure and balloon
dilatation prior to stenting, were encountered similarly
with BMS and DES (table 2). Initial PCI for a bifurcation
lesion and initial PCI with more than one stent were more
frequent in patients with a DES thrombosis, whereas initial
PCI for acute myocardial infarction was performed more
frequently in patients with a BMS thrombosis (table 2). Peak
concentrations of creatinine kinase and troponin following
stent thrombosis, as well as those of inflammatory markers,
did not differ between the two groups (table 3). 
Thirteen (25%) of the 52 patients with a stent thrombosis
died within a few hours of the thrombotic event. A total of
27 (52%) major adverse cardiac events occurred within
18 months: 16 deaths (31%), 7 repeat PCIs, and 4 non-fatal
myocardial infarctions. The composite outcome (death,
recurrent stent thrombosis, myocardial infarction, repeat
revascularization) was also similar 18±6 months after BMS
or DES thrombosis (44% versus 55%, P=NS; table 3 and
figure 1). Most events occurring after 4 months were rela-
ted to a repeat revascularization procedure in patients with
a BMS thrombosis. Overall, at the end of follow-up, 17 (33%)
patients died after a stent thrombosis. 
Factors predictive of survival in univariate analysis were
direct stenting during the first PCI (66% versus 35%, P<0.04)
and the upper level of fibrinogen after stent thrombosis
(4.9±1.6 g/L versus 6.1±2.3 g/L, P<0.04). There was a trend
towards a lower rate of previous myocardial infarction (47%
versus 74%, P=0.06) and a higher concentration of creati-
nine kinase after stent thrombosis (3 629 versus 1667 IU/L,
Table 2 Baseline characteristics and procedural data according to type of stent thrombosis.
DES thrombosis
(n=16)
BMS thrombosis
(n=36)
P
Age (years)±SD 57±15 62±14 NS
Men, n (%) 14 (88) 34 (94) NS
Diabetes mellitus, n (%) 6 (37) 14 (39) NS
Hypertension, n (%) 28 (54) 1799 (51) NS
Smoking history, n (%) 7 (44) 20 (56) NS
Prior MI, n (%) 8 (50) 26 (72) NS
Chronic renal failure, n (%) 1 (6) 5 (14) NS
Prior left ventricular failure, n (%) 2 (13) 14 (39) NS
Initial PCI for acute MI, n (%) 5 (31) 23 (64) 0.03
Initial PCI for bifurcation lesion, n (%) 6 (37) 4 (11) 0.03
Initial multivessel PCI, n (%) 13 (81) 11 (31) 0.03
Initial PCI with >1 stent, n (%) 10 (62) 12 (33) 0.05
Stent diameter (mm)±SD 2.9±0.3 2.9±0.4 NS
Stent length (mm) 24±8 19±7 0.06
Direct stenting, n (%) 7 (44) 22 (61) NS
Antiplatelet discontinuation, n (%) 3 (19) 8 (22) NS
MI: myocardial infarction; NS: non-significant; PCI: percutaneous coronary intervention; SD: standard 
deviation.
Table 3 Biological characteristics and clinical events
according to type of stent thrombosis. 
DES
thrombosis
BMS
thrombosis
P
Biological characteristics 
(peak levels) 
Troponin, μg/L 82±89 158±457 NS
Creatinine kinase, IU/L 1790±1646 2443±4168 NS
C-reactive protein, mg/L 31±49 43±63 NS
Fibrinogen, g/L 4.7±1.6 5.5±1.2 NS
Long-term follow-up 
(18±6 months), n (%) 
Death 6 (37) 11 (31) NS
Recurrent stent thrombosis 1 (6) 4 (11) NS
Non-fatal reinfarction 1 (6) 3 (8) NS
Repeat revascularization 1 (6) 8 (22) NS
Composite outcome 7 (44) 20 (55) NS
NS: non-significant.
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P=0.08) in patients who died. Multivariable analysis identi-
fied no independent predictors of death after stent throm-
bosis.
Discussion
Stent thrombosis remains a rare but dramatic event. Timing
of stent thrombosis, clinical, angiographic and procedural
characteristics, and clinical outcomes appear similar irres-
pective of whether a DES or BMS is used. Interruption of
antiplatelet therapy was encountered in a similar percen-
tage of cases in those with a DES or BMS thrombosis. To our
knowledge, this is the first clinical study comparing the
characteristics and outcomes of documented angiographic
stent thrombosis according to type of stent used. 
Some reports have warned of a possible increase in the
risk of stent thrombosis after implantation of DES in compa-
rison with BMS [6,7]. Despite this fear and theoretical con-
cerns that DES could be associated with a higher rate of
stent thrombosis, the rates of stent thrombosis for DES have
been shown to be similar to those for BMS [3-5,8-14]. More
recently, attention has focused on late stent thrombosis,
especially with DES [6,7]. Late stent thrombosis after
implantation of sirolimus- and paclitaxel-eluting stents has
been reported up to 17 months [15]. Late stent thrombosis
may also occur when patients are stable on single antipla-
telet therapy [16]. However, it is difficult to compare the
incidence of late stent thrombosis reported in the DES era
from that reported in the BMS era due to the paucity of
published reports. For example, a pooled analysis of multi-
centre coronary stent clinical trials demonstrated in 2001
that stent thrombosis occurred in <1.0% of patients under-
going bare-metal stenting of native coronary artery lesions,
but this analysis – like others – was limited to stent throm-
bosis occurring within 30 days after implantation [13]. A
single-centre registry study reported a late stent thrombo-
sis incidence of 0.76% with BMS, which is similar to the
figure reported with DES [17]. Several mechanisms of late
stent thrombosis have been postulated. Farb et al reported
pathological descriptions and showed that stenting across
branch ostia, disruption of adjacent vulnerable plaques,
and extensive plaque prolapse can precipitate late stent
thrombosis. They stated that late stent thrombosis has pro-
bably been under-recognized clinically in the BMS era [18].
According to an interesting study on angiographic patterns
of restenosis, occluded in-stent restenosis occurred in 7% of
cases [19]. In-stent restenoses with total occlusion are dif-
ficult to distinguish from late stent thrombosis. Even if
thrombotic occlusion of the stent up to 2 years after
implantation has been described without platelet treat-
ment discontinuation [20], less attention has been paid to
late stent thrombosis before the expansion of coated
stents. Another study, in which 10 (20%) patients developed
a stent thrombosis, has drawn attention to the fact that
late stent thrombosis can occur after aspirin withdrawal in
patients with a BMS [21]. Hence, the true incidence of late
stent thrombosis with BMS in the “real world” remains
unclear. 
In a large cohort of consecutive patients undergoing DES
implantation, premature discontinuation of antiplatelet
therapy was the most important predictor of stent throm-
bosis. Other key predictors were renal failure, diabetes and
low ejection fraction [22]. In our study, previous myocar-
dial infarction, left ventricular failure and PCI for acute
myocardial infarction were more often encountered in
patients with stent thrombosis. Multivessel stenting and
balloon dilatation before stenting were also more frequent
in patients with stent thrombosis. Discontinuation of anti-
platelet therapy was demonstrated in 21% of cases and was
associated with both DES and BMS stent thrombosis. Base-
line characteristics of patients with and without stent
thrombosis show similar predictive factors for stent throm-
bosis with these devices, except multivessel PCI, which was
more common among patients with a DES. This finding con-
curs with recent data showing the high occurrence of stent
thrombosis among patients treated with DES for multivessel
disease [23].
Timing of stent thrombosis
Thirty-eight (1%) cases of stent thrombosis occurred within
a month of stent implantation and 14 (0.4%) occurred after
4 weeks (i.e. “late” stent thrombosis). This higher rate of
stent thrombosis during the first month is in accordance
with a previous report by Ong et al, in which the rate of
acute/subacute stent thrombosis was higher than that for
late stent thrombosis (mean follow-up of 1.5 years) (1.0%
versus 0.35%, n=2006) [16].
In the present study, the proportion of late stent throm-
bosis versus other stent thrombosis appears similar with
DES (5/16, 31%) and BMS (9/36, 25%). This is in agreement
with recent data showing that DES implantation is not asso-
ciated with a higher rate of stent thrombosis than with BMS,
especially if patients adhere to the recommended dual
antiplatelet therapy regimen [3-5, 24]. However, in a poo-
led analysis of four randomized trials including 5 261
patients with a follow-up of 4 years, stent thrombosis after
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Figure 1. Survival rates (A) after BMS or DES thrombosis, and (B)
without major cardiac events after BMS or DES thrombosis.
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1 year was more common with DES than with BMS, with five
stent thromboses in patients with sirolimus-eluting stents
versus none in patients with BMS, and nine episodes in
patients with paclitaxel-eluting stents versus two in
patients with BMS [6].
Presentation and follow-up
Cardiac death occurred in one-third of patients, mainly in
the first few hours following stent thrombosis, and a major
adverse cardiac event occurred by 18 months in more than
half of the patients. These findings are in agreement with
the known clinical consequences for patients with stent
thrombosis, including short-term mortality rates of up to
25% [13]. In our series, no significant difference in terms of
outcome according to the type of stent was noted, and no
independent predictive factors for cardiac death after
stent thrombosis were identified.
Limitations
This report is confined to patients who presented with acute
symptoms and angiographically proven stent thrombosis
(“definite” stent thrombosis according to the ARC defini-
tion). The data allow us to compare the timing of thrombo-
sis, characteristics and clinical outcomes of patients with
stent thrombosis according to the type of stent – BMS or DES.
Patients with “probable” or “possible” stent thrombosis
(corresponding to unexplained death within 30 days or more
than 30 days after initial PCI) were excluded. The cohort
represents 3 527 consecutive patients from a single centre
who underwent BMS or DES implantation. Subclinical stent
thrombosis may have occurred in some patients but remai-
ned undetected. Conversely, sudden deaths related to stent
thrombosis were not taken into account. 
Conclusions
In our centre, BMS and DES angiographic thrombosis (“defi-
nite”) are very similar in terms of the timing of thrombosis,
clinical, angiographic and procedural characteristics, and
clinical outcomes, with the same risk of late thrombosis
after interruption of antiplatelet therapy in patients with
DES or BMS.
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